IMMUNOCORE HOLDINGS PL

32,45

26-ноября-24 15:45:00

15 мин. задержка

Акции

-0,34

-1,04%

Сегодняшний диапазон

31,66 - 33,66

ISIN

N/A

Источник

NASDAQ

Immunocore to present at upcoming investor conferences

08 ноя 2024 06:00:00 Источник Nasdaq GlobeNewswire
Immunocore reports third quarter financial results and provides a business update

06 ноя 2024 06:00:00 Источник Nasdaq GlobeNewswire
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer

14 сен 2024 02:00:00 Источник Nasdaq GlobeNewswire
Immunocore to present at the 2024 Cantor Global Healthcare Conference

12 сен 2024 15:05:00 Источник Nasdaq GlobeNewswire
Immunocore announces transition of Chief Financial Officer

29 авг 2024 06:00:00 Источник Nasdaq GlobeNewswire
Immunocore reports second quarter financial results and provides a business update

08 авг 2024 06:00:00 Источник Nasdaq GlobeNewswire
Immunocore to report second quarter 2024 financial results and host call on August 8, 2024

01 авг 2024 06:00:00 Источник Nasdaq GlobeNewswire
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma

18 июн 2024 06:00:00 Источник Nasdaq GlobeNewswire
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response

01 июн 2024 06:59:59 Источник Nasdaq GlobeNewswire
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024

31 май 2024 15:05:00 Источник Nasdaq GlobeNewswire
Immunocore to present at the Jefferies Global Healthcare Conference

30 май 2024 15:00:00 Источник Nasdaq GlobeNewswire
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma

29 май 2024 06:00:00 Источник Nasdaq GlobeNewswire
Immunocore reports first quarter financial results and provides a business update

08 май 2024 06:00:00 Источник Nasdaq GlobeNewswire
Immunocore announces upcoming presentation and posters at ASCO 2024

24 апр 2024 09:00:00 Источник Nasdaq GlobeNewswire
Immunocore to present at upcoming investor conferences

04 апр 2024 15:00:00 Источник Nasdaq GlobeNewswire
Immunocore presented two posters at CROI 2024

05 мар 2024 15:30:00 Источник Nasdaq GlobeNewswire
Immunocore to present at upcoming investor conferences

01 мар 2024 06:00:00 Источник Nasdaq GlobeNewswire
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update

28 фев 2024 06:34:03 Источник Nasdaq GlobeNewswire
Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial

22 фев 2024 06:00:00 Источник Nasdaq GlobeNewswire
Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024

21 фев 2024 06:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.